Literature DB >> 20532983

The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG).

P Chérin1, C Rose, C de Roux-Serratrice, D Tardy, D Dobbelaere, B Grosbois, E Hachulla, R Jaussaud, R-M Javier, E Noël, P Clerson, A Hartmann.   

Abstract

BACKGROUND: Gaucher disease (GD), the most prevalent inherited lysosomal storage disorder, is caused by deficient glucocerebrosidase activity. Type 1 GD (GD1), the most common variant, is classically considered non-neuronopathic.
METHODS: We performed a national cross-sectional observational survey-the French Observatoire on Gaucher Disease (FROG)-in patients with GD1 between March 2005 and September 2006. The study included all patients over 18 years of age with confirmed GD1 who attended participating centers for regular follow-up.
RESULTS: One hundred and five patients were included, in whom we studied the prevalence and characteristics of relevant neurological symptoms associated with the neuraxis. Of these, 51 (49%) GD1 patients presented at least one neurological symptom. Four patients (4%) had Parkinson disease and 22 (21%) presented with at least one parkinsonian sign or at least one sign frequently associated with Parkinson disease. Five patients (5%) had a previous diagnosis of peripheral neuropathy. Other central nervous system symptoms were recorded in 20 (19%) patients and other peripheral nervous system symptoms in 39 (37%) patients.
CONCLUSIONS: These data challenge the current classification of GD, and suggest that the three forms of GD each involve a different profile of neurological manifestations.

Entities:  

Mesh:

Year:  2010        PMID: 20532983     DOI: 10.1007/s10545-010-9095-5

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  35 in total

1.  Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

Authors:  T Cox; R Lachmann; C Hollak; J Aerts; S van Weely; M Hrebícek; F Platt; T Butters; R Dwek; C Moyses; I Gow; D Elstein; A Zimran
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

2.  Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease?

Authors:  A Halperin; D Elstein; A Zimran
Journal:  Acta Neurol Scand       Date:  2007-04       Impact factor: 3.209

3.  Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity.

Authors:  Lorraine N Clark; Angelique Nicolai; Shehla Afridi; Juliette Harris; Helen Mejia-Santana; Lisa Strug; Lucien J Cote; Elan D Louis; Howard Andrews; Cheryl Waters; Blair Ford; Steven Frucht; Stanley Fahn; Richard Mayeux; Ruth Ottman; K Marder
Journal:  Mov Disord       Date:  2005-01       Impact factor: 10.338

4.  Chronic polyneuropathies in Vest-Agder, Norway.

Authors:  A Mygland ; P Monstad
Journal:  Eur J Neurol       Date:  2001-03       Impact factor: 6.089

5.  Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Italian General Practitioner Study Group (IGPSG).

Authors: 
Journal:  Neurology       Date:  1995-10       Impact factor: 9.910

Review 6.  Monoclonal gammopathy and neuropathy.

Authors:  Sindhu Ramchandren; Richard A Lewis
Journal:  Curr Opin Neurol       Date:  2009-10       Impact factor: 5.710

7.  Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease.

Authors:  Anders Erikson; Håkan Forsberg; Magnus Nilsson; Marianne Aström; Jan-Eric Månsson
Journal:  Acta Paediatr       Date:  2006-03       Impact factor: 2.299

Review 8.  Gaucher disease: complexity in a "simple" disorder.

Authors:  Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2004 Sep-Oct       Impact factor: 4.797

9.  Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?

Authors:  N Tayebi; J Walker; B Stubblefield; E Orvisky; M E LaMarca; K Wong; H Rosenbaum; R Schiffmann; B Bembi; E Sidransky
Journal:  Mol Genet Metab       Date:  2003-06       Impact factor: 4.797

Review 10.  'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature.

Authors:  M Biegstraaten; I N van Schaik; J M F G Aerts; C E M Hollak
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.750

View more
  27 in total

1.  Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy.

Authors:  Reena V Kartha; James Joers; Marcia R Terluk; Abigail Travis; Kyle Rudser; Paul J Tuite; Neal J Weinreb; Jeanine R Jarnes; James C Cloyd; Gülin Öz
Journal:  J Inherit Metab Dis       Date:  2019-12-17       Impact factor: 4.982

Review 2.  Exploring the link between glucocerebrosidase mutations and parkinsonism.

Authors:  Wendy Westbroek; Ann Marie Gustafson; Ellen Sidransky
Journal:  Trends Mol Med       Date:  2011-07-01       Impact factor: 11.951

Review 3.  Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.

Authors:  Hagit N Baris; Ian J Cohen; Pramod K Mistry
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

Review 4.  Cerebrospinal fluid biomarkers in Parkinson disease.

Authors:  Lucilla Parnetti; Anna Castrioto; Davide Chiasserini; Emanuele Persichetti; Nicola Tambasco; Omar El-Agnaf; Paolo Calabresi
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

Review 5.  Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity.

Authors:  N Gupta; I M Oppenheim; E F Kauvar; N Tayebi; E Sidransky
Journal:  Blood Cells Mol Dis       Date:  2010-09-28       Impact factor: 3.039

6.  The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry.

Authors:  Barry Rosenbloom; Manisha Balwani; Jeff M Bronstein; Edwin Kolodny; Swati Sathe; Andrea R Gwosdow; John S Taylor; J Alexander Cole; Ari Zimran; Neal J Weinreb
Journal:  Blood Cells Mol Dis       Date:  2010-11-10       Impact factor: 3.039

7.  Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study.

Authors:  Elena Lukina; Nora Watman; Elsa Avila Arreguin; Marta Dragosky; Marcelo Iastrebner; Hanna Rosenbaum; Mici Phillips; Gregory M Pastores; Ravi S Kamath; Daniel I Rosenthal; Mathilde Kaper; Tejdip Singh; Ana Cristina Puga; M Judith Peterschmitt
Journal:  Blood       Date:  2010-08-16       Impact factor: 22.113

Review 8.  Glucocerebrosidase is shaking up the synucleinopathies.

Authors:  Marina Siebert; Ellen Sidransky; Wendy Westbroek
Journal:  Brain       Date:  2014-02-14       Impact factor: 13.501

9.  Proton MR Spectroscopy of the brain in children with neuronopathic Gaucher's disease.

Authors:  Ahmed Abdel Khalek Abdel Razek; Ahmed Abdalla; Nahed Abdel Gaber; Abeer Fathy; Ahmed Megahed; Tarek Barakat; Mona Abdel Latif Alsayed
Journal:  Eur Radiol       Date:  2013-06-20       Impact factor: 5.315

Review 10.  Gaucher disease - more than just a rare lipid storage disease.

Authors:  Jaehyeok Roh; Subbaya Subramanian; Neal J Weinreb; Reena V Kartha
Journal:  J Mol Med (Berl)       Date:  2022-01-23       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.